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Introduction 
It is well known that dyslipidaemia is one of the most important causal risk factors for 
coronary heart disease (CHD) (1,2). Although the use of lipid-lowering drugs in primary 
prevention is less cost-effective, at least to some extent in subjects at low total cardiovascular 
(CV) risk, there are absolutely no doubts concerning the imperative use of lipid lowering 
drugs, more precisely statins, for secondary prevention, i.e. in patients with established CHD. 
Randomized controlled trials have clearly proven that LDL-cholesterol (LDL-C) lowering 
with statins can reduce the risk of recurrent cardiovascular events in these patients  (3). It has 
also been shown that further lowering of LDL-C beyond the levels that can be achieved with 
less potent statins or at a lower dose of a given statin, is associated with more CHD 
prevention (3,4).  
Therefore the US guidelines recommend to use high-intensity statin therapy in coronary 
patients in order to achieve a lowering of LDL-C by at least 50% (5).  European guidelines 
recommend a LDL-C goal of < 1.8 mmol/L (<70 mg/dL) or at least 50% reduction of LDL-C 
in patients with documented CHD (2,6). 
The objectives of this study based upon the hospital arm of the EUROASPIRE IV survey 
were to examine how lipid lowering drugs were prescribed in CHD patients at discharge from 
hospitals throughout Europe and how the intake of these drugs  was reported by  the patients 
when they were seen for a standardized interview 1.35 years ( 0.95-1.93) ( median +/- 
interquartile range) later. 
 
Materials and methods 
 
The design, methodology and main results of the EUROASPIRE IV survey have been 
described elsewhere (7). EUROASPIRE IV was a cross-sectional survey conducted at 79 
centres in 24 European countries during May 2012 to April 2013 using standardised methods 
and the same equipment in every centre. In a defined geographical area in each of these 
countries, consecutive male or female patients aged 18-80 years were identified from hospital 
admission and discharge lists or diagnostic registers by the following diagnoses of first or 
recurrent CHD occurring at a time 6-36 months preceding the interview: (i) coronary artery 
bypass grafting (CABG), (ii) percutaneous coronary intervention (PCI), (iii) acute myocardial 
infarction (AMI), and (iv) acute myocardial ischemia (ischemia).  
 
Data collection 
 
Data collection was conducted by trained research staff that reviewed patient medical records, 
interviewed and examined the patients at the hospital using standardized methods and 
instruments at least six months after the hospitalization for the acute event or procedure that 
included them in the survey. Personal and demographic details and drug use were recorded 
and risk factors monitored. Information on advised and adopted lifestyle changes since the 
hospital stay was obtained from questionnaires. 
At the time of interview venous (fasting) blood was drawn for serum total and high-density 
lipoprotein cholesterol (HDL-C), triglycerides, and glycated haemoglobin (HbA1c) while 
LDL-C was calculated according to Friedewald’s formula. The central laboratory was the 
Disease Risk Unit, National Institute for Health and Welfare, Helsinki, Finland, which  is 
accredited by the Finnish Accreditation Service and fulfils the requirements of the standard 
SFS-EN ISO/IEC 17025:2005. Venous blood samples were taken in a sitting position with 
light stasis into a tube containing clot activator (Venosafe, Terumo Europe, Leuven, Belgium) 
for lipid assays and into a potassium EDTA tube (Venosafe) for HbA1c assay. Serum was 
separated by centrifuging at 2000 g for 10 min at room temperature. After that serum was 
aliquoted into two bar-code-labelled tubes and stored together with whole EDTA blood tubes 
locally at a minimum of  -70 °C and then transported frozen to the central laboratory where all 
measurements were performed on a clinical chemistry analyzer (Architect c8000; Abbott 
Laboratories, Abbott Park, Illinois, USA). Total and HDL-C and triglycerides were analysed 
in serum, and HbA1c in whole blood with the following methods: enzymatic method for total 
cholesterol, a homogenous method for direct measurement of HDL-C, an enzymatic glycerol 
phosphate oxidase method for triglycerides, and an immunoturbidimetric method for HbA1c.  
Non-HDL-cholesterol was calculated. 
The laboratory takes part in Lipid Standardization Program organized by CDC, Atlanta, 
Georgia, USA and External Quality Assessment Schemes organized by Labquality, Helsinki, 
Finland. During the course of the study, comprising two months in 2013, the coefficient of 
variation (mean±SD) and systematic error (bias) (mean±SD) were 1.3%±0.2 and 1.7%±1.1 
for total cholesterol, 1.6%±0.5 and – 1.5%±1.6 for HDL-C, 2.3%±0.1 and – 1.2%±2,6 for 
triglycerides, and 1.9%±0.1 and 1.4%±0.2 for HbA1c, respectively. 
Height and weight were measured in light indoor clothes without shoes (SECA scales 701 and 
measuring stick model 220). Obesity was defined as a body mass index  ≥ 30 kg/m2. 
Waist circumference was measured using a metal tape applied horizontally at the point 
midway in the mid-axillary line between the lowest rim of the rib cage and the tip of the hip 
bone (superior iliac crest) with the patient standing. Central obesity was defined as a waist 
circumference of ≥ 88 cm for women and ≥ 102 cm for men. 
Blood pressure was measured twice on the right upper arm in a sitting position using an 
automatic digital sphygmomanometers (Omron M6) and the mean was used for all analyses.  
Breath carbon monoxide was measured in ppm using a smokelyser (Bedfont Scientific, Model 
Micro +). Smoking at the time of interview was defined as self-reported smoking, and/or a 
breath carbon monoxide exceeding 10 ppm. Persistent smoking was defined as smoking at 
interview among patients reporting to be smokers in the month prior to the index event.  
Habitual physical activity was assessed by the International Physical Activity Questionnaire 
(IPAQ). High physical activity was defined as proposed in http://www.ipaq.ki.se/scoring.pdf  
For this substudy all the patients who participated at  the interview were considered (n=7998) 
but 1180 were excluded because of missing LDL-C values, mainly due to the non-fasting state 
at interview; 83 and 87 were excluded because the type or dose of the statin was missing at 
discharge from hospital and/or at the time of the interview respectively. Therefore the results 
from this analysis are based on data of 6648 patients. 
Based on data collected at discharge from hospital and during the interview the patients were 
at both occasions divided in three groups: - on a high-intensity statin therapy - on a moderate or low intensity statin therapy - not on statins 
Drug regimens that are known to lower LDL-C on average by approximately > 50% were 
considered as high-intensity statin therapy (patients taking >=40 mg atorvastatin/day, >=20 
mg rosuvastatin/day, >= 40 mg simvastatin + 10 mg ezetimibe/day, >=20 mg atorvastatin + 
10 mg ezetimibe/day, >= 80 mg fluvastatin+ 10 mg ezetimibe/day). 
All the other drug regimens were considered as low or moderate intensity statin treatment. 
 
Data management 
 
Data management was undertaken at the ESC Euro Heart Survey department, European Heart 
House, Nice, France.  All the data were collected electronically using a unique identification 
number for a country, a centre and an individual. The data was submitted from all centers via 
Internet to the data management centre where checks for completeness, internal consistency 
and accuracy were run. All data were stored under the provisions of the National Data 
Protection Regulations.  
 
Statistical analyses 
........ 
Results 
 
From a total of 6648 CHD patients 9.6% were not on a statin therapy at the time of discharge 
from the hospital; this increased to 14% at interview. 37.6% of the patients were prescribed a 
high-intensity statin therapy at discharge which decreased to 32.7% at the time of the 
interview. Table 1 presents the results regarding lipid lowering drug therapies at discharge 
from hospital and at interview by centers, gender and recruiting event. 
The distribution of  the three statin treatment groups was not very different between genders; 
the small differences suggest that less women were on a statin treatment and that less women 
were on  high-intensity statin therapy both at discharge (p=0.0016) and at interview as 
compared to men (p=0.0056 ). 
When subdivided according to the recruiting event it seems that more patients hospitalized 
because of an acute ischaemic event were not on a statin treatment at the time of the interview 
while less patients who entered the survey after a CABG were on a high-intensity statin, both 
at discharge and at interview (both p<0.0001). 
The largest differences in distribution according to three statin treatment groups were 
observed between the centers. At discharge from hospital there were significant differences: 
in some centers (in Spain, Latvia and Cyprus) less than 5% of the patients were not 
discharged with a statin therapy as compared to more than 20% in the centers from Bosnia-
Herzegovina and the Netherlands. High-intensity statin therapy was prescribed at discharge in 
<10% of the patients in the centers from Germany, Bosnia-Herzegovina and the Netherlands 
in contrast to > 50% in Croatia, France, Ireland, Latvia, Romania Slovenia, Spain and the 
United Kingdom.  
 
Table 1. Statin use at discharge and at interview 
 
 
 Centre 
 
N 
Statin class at discharge Statin class at interview 
No 
%(N) 
Low/mod 
%(N) 
High 
%(N) 
       No 
   %(N) 
Low/Mod 
%(N) 
 High 
%(N) 
 
 
Belgium 
Bosnia Herzegovina  
Bulgaria 
Croatia 
Cyprus 
Czech Republic 
Finland 
France 
Germany 
Greece 
Ireland 
Latvia 
Lithuania 
Netherlands 
Poland 
Romania 
Russian Federation 
 
 
317 
82 
101 
373 
64 
454 
438 
332 
490 
44 
189 
263 
423 
194 
349 
486 
347 
 
 
10.7(34) 
22.0(18) 
10.9(11) 
8.0 (30) 
1.6 (1) 
10.8(49) 
13.5(59) 
6.9 (23) 
11.2(55) 
13.6 (6) 
5.3 (10) 
4.2 (11) 
16.8(71) 
23.2(45) 
5.2 (18) 
5.6 (27) 
7.5 (26) 
 
 
64.0(203) 
72.0 (59) 
77.2 (78) 
18.5 (69) 
90.6 (58) 
47.6(216) 
69.9(306) 
36.1(120) 
84.9(416) 
52.3 (23) 
19.6 (37) 
14.1 (37) 
73.3(310) 
70.1(136) 
47.0(164) 
31.7(154) 
52.2(181) 
 
 
25.2 (80) 
6.1 (5) 
11.9 (12) 
73.5 (274) 
7.8 (5) 
41.6 (189) 
16.7 (73) 
56.9 (189) 
3.9 (19) 
34.1 (15) 
75.1 (142) 
81.7 (215) 
9.9 (42) 
6.7 (13) 
47.9 (167) 
62.8 (305) 
40.3 (140) 
 
 
6.0 (19) 
19.5 (16) 
24.8 (25) 
19.8 (74) 
3.1 (2) 
7.3 (33) 
18.3 (80) 
4.5 (15) 
16.7 (82) 
4.5 (2) 
6.9 (13) 
6.5 (17) 
27.0(114) 
9.8 (19) 
18.3 (64) 
12.1 (59) 
27.7 (96) 
 
 
62.5 (198) 
72.0 (59) 
67.3 (68) 
29.0 (108) 
85.9 (55) 
54.8 (249) 
57.3 (251) 
47.3 (157) 
76.1 (373) 
63.6 (28) 
18.0 (34) 
25.5 (67) 
60.8 (257) 
73.2 (142) 
46.7 (163) 
40.1 (195) 
49.0 (170) 
 
 
31.5 (100) 
8.5 (7) 
7.9 (8) 
51.2 (191) 
10.9 (7) 
37.9 (172) 
24.4 (107) 
48.2 (160) 
7.1 (35) 
31.8 (14) 
75.1 (142) 
68.1 (179) 
12.3 (52) 
17.0 (33) 
35.0 (122) 
47.7 (232) 
23.3 (81) 
Serbia 
Slovenia 
Spain 
Sweden  
Turkey 
Ukraine 
United Kingdom 
 
Gender 
Men 
Women 
 
Recruiting event 
CABG 
PTCA  
AMI 
ISCHAEMIA 
 
All 
368 
215 
162 
323 
199 
229 
206 
 
 
5029 
1619 
 
 
816 
3693 
1451 
688 
 
6648 
8.7 (32) 
5.1 (11) 
3.7 (6) 
7.1 (23) 
10.6(21) 
11.8(27) 
12.6(26) 
 
 
8.9(450) 
11.7 (190) 
 
 
12.9 (105) 
8.5 (314) 
9.6 (140) 
11.8 (81) 
 
9.6 (640) 
 
75.5(278) 
29.8 (64) 
6.2 (10) 
77.7(251) 
45.2 (90) 
75.1(172) 
35.9 (74) 
 
 
52.7(2649) 
52.9 (857) 
 
 
61.3 (500) 
53.3 (1967) 
44.3 (643) 
57.6 (396) 
 
52.7 (3506) 
15.8 (58) 
65.1 (140) 
90.1 (146) 
15.2 (49) 
44.2 (88) 
13.1 (30) 
51.5 (106) 
 
 
38.4(1930) 
35.3 (572) 
 
 
25.9 (211) 
38.2 (1412) 
46.0 (668) 
30.7 (211) 
 
37.6 (2502) 
 
7.3 (27) 
10.2 (22) 
7.4 (12) 
9.3 (30) 
18.6 (37) 
20.5 (47) 
13.1 (27) 
 
 
13.3(671) 
16.1(261) 
 
 
11.2 (91) 
12.9(477) 
15.0(218) 
21.2(146) 
 
14.0(932) 
85.6 (315) 
33.5 (72) 
12.3 (20) 
64.7 (209) 
52.8 (105) 
73.4 (168) 
37.4 (77) 
 
 
53.2 (2674) 
53.5 (866) 
 
 
61.9 (505) 
53.8 (1985) 
47.3 (686) 
52.9 (364) 
 
53.2 (3540) 
7.1 (26) 
56.3 (121) 
80.2 (130) 
26.0 (84) 
28.6 (57) 
6.1 (14) 
49.5 (102) 
 
 
33.5(1684) 
30.4 (492) 
 
 
27.0 (220) 
33.3 (1231) 
37.7 (547) 
25.9 (178) 
 
32.7 (2176) 
 
 
The distribution according to the three statin treatment groups changed also differently 
between centers between the time of the hospital discharge and the interview. In some centers 
(Spain, Poland, Russian federation, Croatia, Ukraine) the proportions of patients not on a 
statin doubled and this was independent of the proportion at hospital discharge ( Table 1). 
In only 6 out of the 24 countries the number of patients on a high-intensity statin therapy had 
increased substantially between the discharge from hospital and interview (Belgium, Finland, 
Germany, Lithuania, the Netherlands and Sweden).  
Among the patients who were not on a statin treatment at discharge, such a therapy was 
initiated in 63.0% (403/640). However, statin therapy was discontinued in 11.6% (695/6008) 
of all the patients who were on a statin therapy at discharge. Table 2 presents the distribution 
of the three statin treatment groups at discharge and at interview. 
 
 
 
 
 
Table 2:  Changes in statin use from discharge to interview (N).  
 
 
 Statin class at interview 
Statin class at discharge  
Total No Low/Mod High 
 No 237 458 237 932 
 Low/Mod 298 2641 601 3540 
 High 105 407 1664 2176 
Total 640 3506 2502 6648 
 
 Among patients who were not treated with a statin or were on a low/moderate dose of a statin 
at discharge from hospital a switch to a high-intensity statin therapy was made in 12.3% 
(512/4146). However, among those on a high-intensity statin therapy at discharge the dosage 
was reduced or the therapy completely stopped in 33.5% (838/2502). 
Women represented 24.4% of the total CHD patient population but 33.8% of all the patients 
who were not on a statin at discharge and at the interview were women (80/237). 
68.4% of the total study population was aged 60 years or more.  
In those not treated with statins at discharge and at interview (n=237) and in those on a 
low/moderate intensity statin therapy at discharge but no statin therapy at interview (n=458) 
the proportion of those aged >=60 years was 75%.  
15.6% of CHD patients reported smoking at interview or had a CO in breath > 10 ppm. That 
proportion was slightly lower (10.7%) in those who had switched from “no statin” at 
discharge to a low/moderate dose statin therapy at interview but it was higher (20.0%) in 
those who moved from “no statin” into “high-intensity statin” group. It was also higher in 
patients who switched from high-intensity treatment to “no statin” therapy at the interview 
(21.9%).  
37.1% of the whole study population was obese: the prevalence of obesity was higher (42.9%) 
in those who had moved from the “no statin” into the high-intensity statin  group and in those 
who had changed from high-intensity to “no statin” at the time of the interview (46.0%). 
One in five patients had insufficient physical exercise; this proportion was comparable in all 
statin treatment groups. 
Self-reported diabetes was prevalent in 25.7% of the patients. It was slightly higher in those 
who were initiated a low/moderate dose treatment after discharge (31.3%) and in those in 
whom the dosage was increased from low/moderate to high-intensity treatment (30.0%). 
Table 3 presents prevalences of smoking, obesity, low physical activity and diabetes at the 
time of the interview according to the different statin therapy status at discharge and at the 
time of the interview. 
  
Table 3. Prevalence of smoking, obesity, low physical activity and diabetes  
 
Statin class  
% Smoking1 
 
% Obesity2 
 
% Low PA3 
 
% Diabetes4 Discharge Interview 
 
No 
No 
No 
 
Low/mod 
Low/Mod 
Low/Mod 
 
High 
High 
High 
 
All 
 
No 
Low/Mod 
High 
 
No 
Low/Mod 
High 
 
No 
Low/Mod 
High 
 
All 
 
 
15.2% (36/237) 
10.7% (32/298) 
20.0% (21/105) 
 
17.7% (81/458) 
15.1% (400/2641) 
15.2% (62/407) 
 
21.9% (52/237) 
15.3% (92/601) 
15.6% (259/1664) 
 
15.6% 
 (1035/6648) 
                     
34.2% (81/237) 
38.5% (114/296) 
42.9% (45/105) 
 
38.1% (174/457) 
35.0% (921/2635) 
38.1% (154/404) 
 
46.0% (109/237) 
37.7% (226/600) 
38.5% (638/1659) 
 
37.1% 
 (2462/6630) 
 
20.9% (33/158) 
22.5% (53/236) 
25.3% (20/79) 
 
21.4% (73/341) 
18.6% (375/2019) 
21.3% (68/320) 
 
22.2% (39/176) 
19.4% (91/468) 
17.9% (236/1322) 
 
19.3%  
(988/5119)      
 
23.6% (56/237) 
31.3% (93/297) 
25.7% (27/105) 
 
21.4% (97/454) 
25.2% (662/2631) 
30.0% (121/404 
) 
27.0% (64/237) 
25.5% (153/599) 
25.8% (426/1653) 
 
25.7% 
 (1699/6617) 
1Self-reported smoking or CO in breath > 10 ppm; 2Body Mass Index ≥ 30 kg/m²;3Low score 
according to IPAQ questionnaire; 4Self-reported diabetes 
 
 
The therapeutic control of LDL-C was clearly related to the lipid lowering drug regimen as 
shown in Table 4. 
 
Table 4 : Therapeutic control of LDL-C at the time of the interview according to the the 
different statin treatment groups . 
 
Statin Class at interview LDL-C < 2.5 mmol/L 
            %     (N) 
LDL-C < 1.8 mmol/L 
           %     (N) 
No statin       28.3       (264/932)       9.0       (84/932) 
Low/moderate intensity       59.4       (2102/3540)      17.5      (618/3540) 
High-intensity       67.9       (1478/2176)       26.6     (578/2176) 
TOTAL        57.8      (3844/6648)       19.3      (1280/6648) 
  
Target values of LDL-C < 2.5 mmol/L or < 1.8 mmol/L at the time of the interview were 
achieved by 57.8% and 19.3% of the patients respectively. Among those who were not on 
statin treatment at that time these LDL-C target levels were achieved by only 28.3% and 9.0% 
respectively.  Nevertheless, among patients on a high-intensity statin therapy these target 
levels were achieved by 67.9 and 26.6% respectively. More men than women and more older 
patients than younger achieved LDL-C < 1.8 mmol/L at interview (Figures 1 and 2).  
 
Figure 1 : Proportions of men and women who achieved LDL-C < 1.8 mmol/L at the 
time of the interview 
 
 
 
  
Figure 2 : Proportions of patients with a fasting LDL-C < 1.8 mmol/L by age groups 
 
 
 
 
  
All patients were also classified in four groups according to the actions which were taken 
regarding statin use between the discharge from the hospital and the interview (see Table 5): 
-  1. No statin therapy at discharge but statin treatment at interview (Initiated). 
-  2. Statin therapy at discharge but no statin treatment at interview (Discontinued). 
-  3. No or low/moderate intensity statin therapy at discharge but high-intensity statin 
treatment at interview (Changes to high). 
-  4. High-intensity statin therapy at discharge but low/moderate intensity statin or no 
treatment at all at interview (Returned to low). 
 
Women were less represented in group 1 and more in group 4. In the older age group more 
patients had their statin dosage reduced or had stopped statins. Time between discharge and 
interview had no effect on the actions taken. More CABG patients were prescribed statin 
treatment between the discharge and the interview if discharged without statin treatment but 
in those discharged on a high-intensity statin, the statin dosage was more often reduced. In 
patients with an acute ischaemic event and in patients who continued smoking  less statin 
treatment was initiated if discharged without any statin therapy and more discontinuation of 
therapy occurred. More actions concerning statin treatment of all kinds had been taken in the 
patients who were found to be obese or sedentary at the time of interview. Patients with 
diabetes were more represented in group 1. 
As expected the proportions of patients who have achieved LDL-C < 1.8 mmol/L at interview 
were greater in those in whom statin treatment was initiated between discharge and interview  
but to whom statins were not prescribed at discharge and in those in whom therapy was 
switched to a high-intensity statin treatment (Table 5). 
 
 
 
 
  
 
 
 
 
 
 
Table 5. Action taken regarding statin use  
 
 Action taken regarding statin use 
% Initiated1 % Discontinued2 % Changed to 
high3 
% Returned to 
low4 
 
Gender 
Men 
Women 
 
Age  
< 60 years 
≥ 60 years 
 
Time discharged 
 
 
68.3% (233/341)  
61.2% (79/129)  
 
 
66.4% (85/128)  
66.4% (227/342)  
 
                      
 
                      
 10.7% (380/3548) 
 12.6% (134/1067) 
    
                   
  9.8% (143/1456) 
 11.7% (371/3159) 
     
                  
                      
                      
 13.0% (306/2358) 
 11.5% (89/775) 
 
                      
 14.5% (126/866) 
 11.9% (269/2267) 
      
                 
                      
                      
 31.4% (480/1531) 
 38.7% (163/421) 
 
                      
 30.6% (220/718) 
 34.3% (423/1234) 
   
                    
< 1 year 
≥ 1 year 
 
Recruiting 
diagnosis 
CABG 
PTCA 
AMI 
ISCHAEMIA 
 
Smoking 
No 
Yes 
 
Obesity 
No  
Yes 
 
Low physical 
activity 
No 
Yes 
 
 66.6% (225/338)  
65.9% (87/132)  
 
                      
 
82.4% (56/68)  
 68.9% (175/254)  
 63.1% (65/103)  
 35.6% (16/45)  
 
                      
 67.3% (272/404)  
 60.6% (40/66)  
 
                      
 64.9% (192/296)  
 69.0% (120/174)  
 
                      
 65.8% (241/366)  
 68.3% (71/104)  
 
 11.6% (368/3172) 
 10.1% (146/1443) 
   
                    
 
  9.2% (50/541) 
 10.6% (283/2661) 
 11.9% (117/981) 
 14.8% (64/432) 
  
                     
 10.7% (421/3937) 
 13.7% (93/678) 
         
              
 10.5% (305/2897) 
 12.2% (209/1718) 
     
                  
 10.8% (403/3742) 
 12.7% (111/873) 
   
 13.1% (291/2213) 
 11.3% (104/920) 
   
                    
  
13.2% (60/453) 
 12.1% (215/1781) 
 14.2% (81/569) 
 11.8% (39/330) 
          
             
 12.3% (331/2682) 
 14.2% (64/451) 
       
                
 11.6% (233/2014) 
 14.5% (162/1119) 
   
                    
 12.2% (307/2519) 
 14.3% (88/614) 
  
 33.4% (433/1297) 
 32.1% (210/655) 
     
                  
  
38.5% (60/156) 
 32.7% (371/1134) 
 31.3% (161/515) 
 34.7% (51/147) 
 
                      
 32.7% (543/1659) 
 34.1% (100/293) 
 
                      
 31.6% (372/1179) 
 35.1% (271/773) 
    
                   
 32.3% (514/1589) 
 35.5% (129/363) 
 
Diabetes 
No 
Yes 
 
LDL-C < 1.8 
mmol/L 
No                                        
Yes 
 
                      
 64.5% (223/346)  
 71.8% (89/124)  
 
 
 
8.0% (19/237) 
23.1% (93/403)          
 
                    
 11.5% (394/3434) 
 10.2% (120/1181) 
 
 
 
20.8%(1103/5313) 
9.4% (65/695) 
                     
 12.1% (283/2332) 
 14.0% (112/801) 
 
 
 
14.9%(541/3634) 
23.6% (121/512) 
                      
 32.8% (475/1448) 
 33.3% (168/504) 
 
 
 
27.5%(457/1664) 
19.2%(161/838) 
1 : No statin at discharge: %  statin at interview 
2 : Statin at discharge: % no statin at interview 
3 : No or low/moderate intensity statin at discharge: % high intensity statin at interview 
4 : High intensity statin at discharge: % low/moderate intensity statin or no statin at interview 
 
 
 
 
 Table 6. Lipid levels at goal: LDL-C vs. Non-HDL-cholesterol 
 
 
Non-HDL-C  
LDL-C  
Total < 1.8 mmol/L ≥ 1.8 mmol/L 
    
< 2.6 mmol/L 
 
1124 850 1974 
≥ 2.6 mmol/L 
 
156 4518 4674 
Total 1280 5368 6648 
 
 
Among 1280 patients who achieved the LDL-C target, 156 (12,2%) were not at goal for non-
HDL-C. If only non-HDL-C had been used as a target, then 850 out of the 1974 patients (43.0 
%) who were at goal for non-HDL-C would not achieve LDL-C target value. Among all 
patients in EUROASPIRE IV 1124/6648 (16.9%) were at goal for both LDL-C and non-
HDL-C.  
A similar analysis was made for the 1699 patients with self reported diabetes and these results 
are presented in table 7. 
 
Table 7. Lipid levels at goal: LDL-C vs Non-HDL-cholesterol in patients with diabetes 
 
 
Non-HDL-C  
LDL-C  
Total < 1.8 mmol/L ≥ 1.8 mmol/L 
 
< 2.6 mmol/L 
 
 
411 
 
176 
 
587 
≥ 2.6 mmol/L 
 
74 1038 1112 
Total 485 1214 1699 
 
 
 
Among the 485 CHD patients with diabetes who achieved LDL-C target, only 74 (15.3%) 
were not at goal for non-HDL-C. If only non-HDL-C had been used as a target 176 out of the 
587 (30.0 %) CHD patients with diabetes who were at goal for non-HDL-C would not be at 
goal for LDL-C. Among all CHD patients with self-reported diabetes in EUROASPIRE IV 
411/1699 (24.0%) were at goal for both LDL-C and non-HDL-C. 
 
Discussion 
 
The results of the EUROASPIRE IV survey concerning lipid lowering therapy in CHD 
patients show that despite the clear evidence of the benefits of lipid-lowering treatment with 
statins in secondary prevention, many coronary patients with dyslipidaemia are still 
inadequately treated and a significant number of patients on lipid-lowering therapy is still not 
reaching the LDL-C treatment goals. According to these results every tenth patient in 
European centers has been discharged from the hospital after a coronary event without any 
statin treatment and only one third of CHD patients were prescribed a high-intensity statin 
therapy at discharge. This happens in spite of the recommendations of both European and US 
guidelines (2,5). On average this is much better than some recently published results for 
certain European countries (not included in this survey) indicating that more than one third of 
patients do not receive a statin prescription at hospital discharge after an MI (8). 
It is also worrying that 6-36 months after a CHD event the number of patients without any 
statin therapy increased by about 50% and that the number of patients on high-intensity statin 
treatment decreased significantly. The reasons why the physicians often prescribe low-
intensity statin treatment instead of high-intensity therapy when needed are different and 
complex but quite often it is the fear of adverse effects of statins (9,10) Even more feared are 
the patients who are frequently confused with the information from the media suggesting that 
statins have many serious adverse effects so they stop taking the statins after some time or do 
not adhere to the prescribed dose (9,11,12). Although high levels of adherence are 
undoubtedly associated with reductions in adverse clinical CHD outcomes, including all-
cause mortality and fatal and nonfatal cardiovascular events (the most consistent benefits 
being at adherence levels 80% or greater) while poor statin adherence is associated with 
increased risk of adverse CHD outcomes, taken in general non-adherence to statin therapy is a 
big problem (13,14). It is well known that adherence to statin therapy declines with time and 
according to a study on patients with established CHD falls to 71% after six months of 
treatment, and declines to only 45% after three years (15). Our results are much better than 
these but they were obtained several years later than the mentioned study. However, it is also 
well known that patients with established CHD have better adherence to statins than those 
without proven CHD (16). Statin resistance and/or intolerance might be another reason, at 
least for some patients, why did the number of patients without statin treatment in our survey 
increase and the number of those on high-intensity treatment decrease between the CHD event 
and interview (17) 
Gender issue should be particularly addressed. Although only every fourth patient with CHD 
in EUROASPIRE IV survey was a women, the fact that much less women were on statin 
treatment and that less women were on high-intensity statin therapy both at discharge and at 
interview as compared to men deserves special attention and concern. It reflects the 
phenomenon registered in some other studies as well. For example, it has been shown that 
women, particularly younger women and women with ST-segment elevation AMI, are less 
likely to be prescribed evidence-based treatment at discharge including statins than their male 
counterparts (18). This gap between men and women did narrow over time during the last 15 
years in most parts of the world, including those outside Europe, but it still exists (19). 
According to the results of this study CHD patients older than 60 years get much less 
prescribed statin therapy than the younger patients. The dose of a statin is also more often 
reduced in these patients and they also stop taking statins after a CHD event more often. This 
is similar to the data on primary prevention of CHD indicating that older people often do not 
receive proper primary prevention treatment in general and that low use of statins in primary 
prevention when they are concerned, is more rule than the exception (20,21). Nevertheless, a 
substantial increase in prevalence and incidence of prescribing statins in the older subjects 
with the greatest relative increase in those older than 80 years can be seen in the last decade 
across all CV risk categories, at least in most developed countries (22). 
Significant differences in distribution according to three statin treatment groups which were 
observed between the centers from different countries are very difficult to interpret. One 
might suppose that they reflect different socioeconomic situations and different 
reimbursement policies. Financial constraints might be responsible for this, especially in low- 
and middle-income European countries. This could maybe explain, for instance, why more 
than 20% patients were discharged after a CHD event without a statin and why a high-
intensity statin therapy was prescribed at discharge in only <10% of the patients in the centers 
from Bosnia-Herzegovina. However, if this is true, it is hard to understand why a similar 
percentage was seen in the centers from the Netherlands or why high-intensity statin therapy 
was prescribed at discharge in only <10% of the CHD patients in the centers from Germany, 
which are both high-income countries.  
On the other hand, variation between centres within a certain country was even larger than the 
between-country variation indicating that the local policy plays a prominent role so that the 
differences between countries in the use of statins (as well as their changes) should be 
interpreted with great caution. So the proportions of patients discharged without a statin in 
some countries with multiple centres differed  up to 7 fold. The proportions of patients not 
using a statin at the time of interview differred between centres in a single county even more – 
up to 22 fold. 
It is also of great concern that in only every fourth European country the number of CHD 
patients on a high-intensity statin therapy had increased between the discharge from hospital 
and interview - almost all of them being high-income countries. This cannot be explained only 
by economic reasons. Financial constrains could be a possible explanation for lower-income 
countries as it has been shown that higher copayments act as a disincentive for persistent and 
adherent use of statin therapy, but this might also not be the only explanation even for these 
countries (23,24). 
It is worrying that only every eighth CHD patient who was not treated with a statin or was on 
a low/moderate dose of a statin at discharge from hospital switched afterwards to a high-
intensity statin therapy. Even more disturbing is that in one third of patients on a high-
intensity statin therapy at discharge the dosage was later reduced or the therapy completely 
stopped. We believe that this might reflect the lack of their physicians’ knowledge or 
adherence to the guidelines (11,12,25).  
The therapeutic control of LDL-C in EUROASPIRE IV survey was clearly related to the 
intensity of LDL-C lowering drug regimen. A substantial number of CHD patients on lipid-
lowering drugs who did not achieve the LDL-C target levels is of concern indicating that 
statins are still either not used as effectively as they should be or that there is poor patient 
compliance, or both. The same phenomenon was also seen in EUROASPIRE III (26). One of 
the possible reasons might be that despite the fact that the majority of cardiologists and 
primary care physicians support the concept of preventive cardiology and treatment of LDL-C 
to the target values, this still does not always reflect in their current practice, the knowledge of 
graduated medical students on dyslipidemia and its treatment is not satisfactory and the 
general public perceptions, knowledge and awareness of CVD risk factors including 
dyslipidaemia are insufficient (11,12,27). Obviously, there are still challenges and many 
barriers to implement the CVD prevention guidelines, even when dyslipidaemia treatment is 
concerned (28).  
In the ECS/EAS guidelines it is recommended to use non-HDL-C as a secondary target 
particularly in patients with diabetes or obesity, because in these patients atherogenic particles 
other than LDL may also be important and non-HDL-C measures account for all atherogenic 
lipoproteins (2,6). Therefore, non-HDL-C is believed to provide in these patients maybe even 
a better estimate of CVD risk than LDL-C. In CHD patients the goal for non-HDL-C is set at 
< 2.6 mmol/L (~100 mg/dL). It has been shown that patients who achieved LDL-C target 
levels without reaching target non-HDL-C levels had a 32% increased risk of CHD events 
compared with those who achieved dual target levels for LDL-C and non-HDL-C (29).  A 
possible explanation might be that non-HDL-C is a better predictor of plaque inflammation, 
and therefore its vulnerability, than LDL-C (30,31). In our survey only 12.2% CHD patients 
who achieved LDL-C target level were not at goal for non-HDL-C and only 25.3% CHD 
patients with diabetes who achieved LDL-C target were not at goal for non-HDL-C.  
But on the contrary, if only the non-HDL-C target would have been used, much more patients 
would not have been at goal for LDL-C. Therefore it is recommended to continue to use LDL-
C as a primary target and to look at non-HDL-C in patients who are at goal for LDL-C, 
particularly those with diabetes or obesity. The results presented here indicate that statins are 
the treatment of choice for a vast majority of these patients if applied properly and in adequate 
intensity. However, as every fourth CHD patient with diabetes who achieved LDL-C target 
value still has a residual CVD risk, this has to be taken into consideration and other additional 
therapeutic options for these patients should be considered. In this context it is interesting that 
very few CHD patients, including those with diabetes,  were prescribed fibrates together with 
a statin although it is well known that many of these patients have atherogenic dyslipidaemia 
which is characterised not only by increased LDL-C but primarily by increased levels of 
triglycerides and decreased HDL-C (32,33,34,35,36). In these patients even more attention 
should be directed towards other modifiable CV risk factors and combination of lipid 
lowering drugs might be considered to get LDL-C even lower resulting in more prevention as 
shown in the IMPROVE-IT trial (37). It could be hypothesized that although today most of 
the patients with dyslipidemia are treated with statins as monotherapy, this might change in 
the near future (38). The pattern could follow what happened with antihypertensive treatment 
which was also several decades ago based upon monotherapy. However, today combinations 
of two, three or even four drugs lowering the blood pressure by influencing different blood-
pressure-lowering mechanisms are widely used to achieve the treatment goals as defined by 
the guidelines. In the meantime, the results of outcome trials with other lipid lowering drugs 
combinations are eagerly awaited.  
 
Abstract 
 
Objective. Since dyslipidaemia is one of the most important risk factors for coronary heart 
disease (CHD), lowering of LDL-cholesterol (LDL-C) causes significant reduction in 
morbidity and mortality, particularly in patients with established CHD. The aim of this survey 
was to assess how statins were prescribed in CHD patients at discharge after a coronary event 
from hospitals throughout Europe and how the intake of these drugs was reported by the 
patients when they were seen more than one year later in relationship with their achieved 
LDL-C levels. 
Methods.  6648 CHD patients’ data from centres in 24 European countries were gathered 
using standardized methods. Lipid measurements were performed in one central laboratory. 
Patients were divided in three groups: high-intensity statin therapy, moderate or low intensity 
statin therapy and no statin therapy at all.  
 Results. 90.4% CHD patients were on statin therapy at the time of discharge from the 
hospital which decreased to 86% one year later. Only 37.6% of these patients were prescribed 
a high-intensity statin at discharge which even decreased to 32.7% later. In only 6 countries 
(all of them high-income countries) the number of patients on a high-intensity statin therapy 
increased substantially after the hospital discharge. It is worrying that statin therapy was 
discontinued in 11.6% of the patients who were on a statin therapy at discharge and that only 
19.3% of all CHD patients achieved target values of LDL-C < 1.8 mmol/L one year after the 
event.  
Conclusions. Too many CHD patients with dyslipidaemia are still inadequately treated and 
most of these patients on statin therapy are not achieving the treatment targets. Therapeutic 
control of LDL-C is clearly related to the intensity of lipid lowering drug regimen after the 
CHD event indicating that a considerable potential still exists throughout Europe to reduce 
CHD mortality and morbidity rates through more efficient LDL-C lowering. 
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